ACE Inhibitors Market - Forecast(2024 - 2030)

ACE Inhibitors Market Overview

ACE Inhibitors Market size is estimated to reach $8.1 billion by 2026, growing at a CAGR of 3.6% during the forecast period 2021-2026. Angiotensin-converting enzyme (ACE) inhibitors are a class of medications that help in relaxing the arteries and veins for lowering blood pressure. These inhibitors prevent an enzyme from producing angiotensin II in the body. ACE Inhibitors were increasingly being adopted across the world owing to the rise in the prevalence of heart failures and the growing adoption of antihypertensive medicines. The rise in the adoption of Lisinopril drugs for treating high blood pressure, increase in the demand for angiotensin-converting enzyme inhibitors with high angiotensin-converting enzyme affinity, the growing adoption of Perindopril drugs for hypertension, and the rise in the research and development activities for developing advanced drugs are the factors that are set to drive the growth of the ACE Inhibitors Market for the period 2021-2026.

Report Coverage

The report: “ACE Inhibitors Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the ACE Inhibitors Market.

By Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others.
By Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others.
By End User: Hospitals, Pharmacies, Online Drug Stores, and Others.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

• Geographically, the North America ACE Inhibitors Market accounted for the highest revenue share in 2020, and it is poised to dominate over the period 2021-2026 owing to the rise in the adoption of angiotensin-converting enzyme inhibitors.
• The increase in the demand for Lisinopril drugs for treating high blood pressure is driving the Lisinopril segment. However, the high cost of ACE inhibitors is one of the major factors that is said to reduce the growth of the ACE Inhibitors Market.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the ACE Inhibitors Market report.

ACE Inhibitors Market Segment Analysis-By Drug Type

The ACE Inhibitors Market based on Drug Type can be further segmented into Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others. The Lisinopril segment held the largest share owing to the factors such as the rise in the demand for Lisinopril drugs for treating high blood pressure and an increase in the adoption of Lisinopril for improving survival after a heart attack. According to the statistics, the number of Lisinopril prescriptions in the United States has increased to 91,862,708, which is driving the growth of the ACE Inhibitors Market. The Perindopril segment is estimated to be the fastest-growing segment with a CAGR of 4.1% over the period 2021-2026. This growth is owing to the factors such as the increase in the demand for angiotensin-converting enzyme inhibitors with high angiotensin-converting enzyme affinity and the rise in the adoption of antihypertensive medicines.

ACE Inhibitors Market Segment Analysis-By Application

The ACE Inhibitors Market based on the Application can be segmented into Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others. The Heart Failure segment held the largest share in 2020 owing to the factors such as the rise in the research and development activities for developing advanced drugs for the treatment of heart failure and the growing demand for Lisinopril for improving survival after a heart attack. According to the U.S. Department of Health & Human Services, 6.2 million adults in the United States are being affected by heart failure. This rapid rise in the prevalence of heart failure is driving the growth of the ACE Inhibitors Market. The Hypertension segment is estimated to be the fastest-growing segment with a CAGR of 4.4% over the period 2021-2026. This growth is owing to the factors such as the growing demand for Perindopril drugs for hypertension and the increasing demand for antihypertensive medicines in developing nations.

ACE Inhibitors Market Segment Analysis-By Geography

The ACE Inhibitors Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share, with 36% of the overall market in 2020. The growth in this segment is owing to the factors such as the increasing demand for angiotensin-converting enzyme inhibitors and the growing research and development activities for developing advanced Inhibitors. The rise in the adoption of Lisinopril for improving survival after a heart attack is driving the growth of the ACE Inhibitors Market. According to statistics, the number of visits to physician offices with hypertension for the primary diagnosis has increased to 33.6 million. Asia-Pacific segment is estimated to be the fastest-growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as the growing demand for antihypertensive medicines in developing nations and the rise in the prevalence of heart failures.

ACE Inhibitors Market Drivers

Increase in the Adoption of Prescription Medicines for Hypertension is Expected to Boost Product Demand

According to the Centers for Disease Control and Prevention, the percent of adults with hypertension aged 20 and over has increased to 49.6% in the United States. Moreover, the key players are focusing on developing Perindopril drugs for hypertension, which is one of the major factors driving the growth of the ACE Inhibitors Market.

The Rise in the Prevalence of Heart Failure will Provide New Growth Avenues to the Industry Growth

According to the National Center for Biotechnology Information (NCBI), 26 million people across the world are being affected by heart failures and are increasing dramatically in the aging population. Moreover, the rise in the demand for Lisinopril drugs for improving survival after a heart attack is further propelling the demand for the ACE Inhibitors Market.

ACE Inhibitors Market Challenges                   

High Cost of ACE Inhibitors may Pose Hindrance to Market Growth

The key players in the market are increasing their investment to carry out various research and development activities for developing Lisinopril drugs for treating high blood pressure. However, the cost of ACE inhibitors ranges from $15 to $30, which is one of the major factors estimated to reduce the growth of the ACE Inhibitors Market.

ACE Inhibitors Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the ACE Inhibitors Market. Key companies of this market include:

1. AstraZeneca
2. Abbott
3. Bausch Health Companies Inc
4. Pfizer Inc.
5. AbbVie
6. Merck KGaA
7. Novartis AG
8. Johnson & Johnson
9. Sanofi S.A.
10. Eli Lilly and Company

Relevant Links:

Antihypertensive Drugs Market - Forecast (2021 - 2026)

Report Code: HCR 0143

Proteinuria Treatment Market - Forecast (2021 - 2026)

Report Code: HCR 0358 

For more Lifesciences and Healthcare Market reports, please click here